Hua Peng

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 26

Top Topics

Respiratory Syndrome Coronavirus

Saccharomyces Cerevisiae

Radiofrequency Ablation

Top Venues

Nature communications

Science immunology

This page only lists publications with an associated author ORCID identifier.

Publications

Hang Zhou, Wenjun Wang, Hairong Xu, Yong Liang, Jiyu Ding, Mengjie Lv, Boyang Ren, Hua Peng, Yang-Xin Fu, Mingzhao Zhu
Metabolic reprograming mediated by tumor cell-intrinsic type I IFN signaling is required for CD47-SIRPα blockade efficacy. Nature communications 15 (1) (2024)
Hang Zhou, Wenjun Wang, Hairong Xu, Yong Liang, Jiyu Ding, Mengjie Lv, Boyang Ren, Hua Peng, Yang-Xin Fu, Mingzhao Zhu
Metabolic reprograming mediated by tumor cell-intrinsic type I IFN signaling is required for CD47-SIRPα blockade efficacy. Nature communications 15 (1) (2024)
Zhuangzhi Zou, Jiao Shen, Diyuan Xue, Hongjia Li, Longxin Xu, Weian Cao, Wenyan Wang, Yang-Xin Fu, Hua Peng
Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8 + T cells for systemic antitumor responses. Nature communications 15 (1) (2024)
Zhuangzhi Zou, Jiao Shen, Diyuan Xue, Hongjia Li, Longxin Xu, Weian Cao, Wenyan Wang, Yang-Xin Fu, Hua Peng
Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8 + T cells for systemic antitumor responses. Nature communications 15 (1) (2024)
Hang Zhou, Wenjun Wang, Hairong Xu, Yong Liang, Jiyu Ding, Mengjie Lv, Boyang Ren, Hua Peng, Yang-Xin Fu, Mingzhao Zhu
Metabolic reprograming mediated by tumor cell-intrinsic type I IFN signaling is required for CD47-SIRPα blockade efficacy. Nature communications 15 (1) (2024)
Zhuangzhi Zou, Jiao Shen, Diyuan Xue, Hongjia Li, Longxin Xu, Weian Cao, Wenyan Wang, Yang-Xin Fu, Hua Peng
Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8 + T cells for systemic antitumor responses. Nature communications 15 (1) (2024)
Zhuangzhi Zou, Jiao Shen, Diyuan Xue, Hongjia Li, Longxin Xu, Weian Cao, Wenyan Wang, Yang-Xin Fu, Hua Peng
Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8 + T cells for systemic antitumor responses. Nature communications 15 (1) (2024)
Hang Zhou, Wenjun Wang, Hairong Xu, Yong Liang, Jiyu Ding, Mengjie Lv, Boyang Ren, Hua Peng, Yang-Xin Fu, Mingzhao Zhu
Metabolic reprograming mediated by tumor cell-intrinsic type I IFN signaling is required for CD47-SIRPα blockade efficacy. Nature communications 15 (1) (2024)
Hua Peng, Yang-Xin Fu
Towards developing a variant-proof SARS-CoV-2 vaccine. Cell research 33 (1) (2023)
Hua Peng, Yang-Xin Fu
Towards developing a variant-proof SARS-CoV-2 vaccine. Cell research (2023)
Hua Peng, Yang-Xin Fu
Towards developing a variant-proof SARS-CoV-2 vaccine. Cell research 33 (1) (2023)
Hua Peng, Yang-Xin Fu
Towards developing a variant-proof SARS-CoV-2 vaccine. Cell research 33 (1) (2023)
Chao-Yang Meng, Shiyu Sun, Yong Liang, Hairong Xu, Chao Zhang, Min Zhang, Fu-Sheng Wang, Yang-Xin Fu, Hua Peng
Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. Gut (2022)
Yifan Lin, Jing Sun, Xuezhi Cao, Xiuye Wang, Xi Chen, Hairong Xu, Jin-Cun Zhao, Yang-Xin Fu, Hua Peng
Non-adjuvanted interferon-armed RBD protein nasal drops protect airway infection from SARS-CoV-2. Cell discovery 8 (1) (2022)
Hua Peng, Yang-Xin Fu
Innovative adjuvant augments potency of a SARS-CoV-2 subunit vaccine. Cell research 32 (4) (2022)
Zhiren Zhang, Qiaren He, Wei Zhao, Yong Li, Jiaming Yang, Zhenxiang Hu, Xi Chen, Hua Peng, Yang-Xin Fu, Long Chen, Ligong Lu
A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains. Journal of clinical medicine 11 (14) (2022)
Chuanhui Han, Victoria Godfrey, Zhida Liu, Yanfei Han, Longchao Liu, Hua Peng, Ralph R Weichselbaum, Hasan Zaki, Yang-Xin Fu
The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation. Science immunology 6 (59) (2022)
Jiao Shen, Zhuangzhi Zou, Jingya Guo, Yueqi Cai, Diyuan Xue, Yong Liang, Wenyan Wang, Hua Peng, Yang-Xin Fu
An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery. The Journal of experimental medicine 219 (12) (2022)
Diyuan Xue, Benjamin Moon, Jing Liao, Jingya Guo, Zhuangzhi Zou, Yanfei Han, Shuaishuai Cao, Yang Wang, Yang-Xin Fu, Hua Peng
A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors. Science immunology 7 (67) (2022)
Shiyu Sun, Yueqi Cai, Tian-Zhang Song, Yang Pu, Lin Cheng, Hairong Xu, Jing Sun, Chaoyang Meng, Yifan Lin, Haibin Huang, Fang Zhao, Silin Zhang, Yu Gao, Jian-Bao Han, Xiao-Li Feng, Dan-Dan Yu, Yalan Zhu, Pu Gao, Haidong Tang, Jincun Zhao, Zheng Zhang, Jiaming Yang, Zhenxiang Hu, Yang-Xin Fu, Yong-Tang Zheng, Hua Peng
Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. Cell research 31 (9) (2021)
Shiyu Sun, Xi Chen, Jingjing Lin, Junwen Ai, Jiaming Yang, Zhenxiang Hu, Yang-Xin Fu, Hua Peng
Broad neutralization against SARS-CoV-2 variants induced by a next-generation protein vaccine V-01. Cell discovery 7 (1) (2021)
Weinan Qiu, Qingyang Zhang, Rui Zhang, Yangxu Lu, Xin Wang, Huabin Tian, Ying Yang, Zijuan Gu, Yanan Gao, Xin Yang, Guanshen Cui, Baofa Sun, Yanan Peng, Hongyu Deng, Hua Peng, An-Gang Yang, Yun-Gui Yang, Peng-Yuan Yang
N6-methyladenosine RNA modification suppresses antiviral innate sensing pathways via reshaping double-stranded RNA. Nature communications 12 (1) (2021)
Qi Peng, Xiangyan Qiu, Zihan Zhang, Silin Zhang, Yuanyuan Zhang, Yong Liang, Jingya Guo, Hua Peng, Mingyi Chen, Yang-Xin Fu, Haidong Tang
PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nature communications 11 (1) (2020)
Wenjun Wang, Xiaoxiao Zhou, Yingjie Bian, Shan Wang, Qian Chai, Zhenqian Guo, Zhenni Wang, Ping Zhu, Hua Peng, Xiyun Yan, Wenhui Li, Yang-Xin Fu, Mingzhao Zhu
Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. Nature nanotechnology 15 (5) (2020)
Zhichen Sun, Zhenhua Ren, Kaiting Yang, Zhida Liu, Shuaishuai Cao, Sisi Deng, Lily Xu, Yong Liang, Jingya Guo, Yingjie Bian, Hairong Xu, Jiyun Shi, Fan Wang, Yang-Xin Fu, Hua Peng
Author Correction: A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nature communications 11 (1) (2020)
Zhichen Sun, Zhenhua Ren, Kaiting Yang, Zhida Liu, Shuaishuai Cao, Sisi Deng, Lily Xu, Yong Liang, Jingya Guo, Yingjie Bian, Hairong Xu, Jiyun Shi, Fan Wang, Yang-Xin Fu, Hua Peng
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nature communications 10 (1) (2019)